Object. The goal of this study was to determine the rates of mortality and morbidity associated with the embolization of arteriovenous malformations (AVMs) of the brain and to analyze the factors related to embolization-related complications.
NDOVASCULAR embolization serves three purposes in the treatment of AVMs in the brain. It is performed to attempt a cure; as adjunctive treatment along with radiosurgery or surgery; or for targeted partial (palliative) embolization of otherwise untreatable brain AVMs. These procedures are associated with potential incidences of morbidity and mortality. Treatment combining multiple therapeutic modalities results in additive risk. The risk of treatment must then be balanced against the natural history of AVM hemorrhage and treatment-related incidences of morbidity and mortality. Ondra and colleagues 10 conducted a study on the natural history of AVMs of the brain. According to their findings, these lesions carry a 4% per year risk of hemorrhage and a 1% per year risk of mortality. The combined rate of mortality and major morbidity was calculated to be 2.7% per year. Over a mean follow-up period of 23.7 years, 23% of patients died as a direct result of AVM hemorrhage. In the Toronto AVM series, researchers found a 3.4% annual risk of hemorrhage. 12 In a follow-up review of the patients who experienced hemorrhage, 17% died, 38% had a permanent neurological deficit, and only 45% made a complete recovery. 13 We reviewed our large experience with embolization of brain AVMs, in which we used nearly exclusively liquid embolic agents, to provide overall rates of morbidity and mortality and to determine factors that could predispose to these complications.
Clinical Material and Methods

Patient Population
The University of Toronto Brain Vascular Malformation Study Group has assessed 887 patients with brain AVMs in a multidisciplinary clinic consisting of neurosurgeons, interventional neuroradiologists, and radiosurgery specialists. Data were collected retrospectively from 1984 to 1991 and prospectively thereafter. The patients in this study underwent brain AVM embolization between November 1984 and September 2002. The embolization procedures were performed at Toronto Western Hospital and the Hospital for Sick Children. Patients with vein of Galen malformations and cranial dural AVFs were excluded from the study population.
Case Investigation
Relevant clinical files as well as neuroimaging studies were reviewed. Catheter-assisted angiographic images, including microcatheter injections, were collected from every embolization procedure performed between 1984 and the present. Research assistants routinely update a computerized database. Collected data include demographic information, mode of AVM presentation, findings of the neuro-logical examination, technical aspects of the embolization procedure, and AVM angioarchitectural data. The AVMs were classified using the Spetzler-Martin grading scale. 14 Embolization sessions had four possible goals: cure, adjunctive treatment before radiosurgery, adjunctive treatment before surgery, or palliation in patients with otherwise incurable AVMs.
Endovascular Embolization
The technique of endovascular embolization evolved during the time period covered by this study. 4 From 1984 to 1994 almost all embolization procedures were performed with the aid of neuroleptic anesthesia. Amytal testing was used in selected patients until 1986. Since 1995, general anesthesia has been routinely induced, and biplane digital subtraction angiography has been used since 1999. All procedures start with femoral artery sheath placement. The patient undergoes systemic anticoagulation induced with a 100-IU/kg intravenous heparin bolus followed by 1000 U heparin per hour throughout the embolization procedure. A No. 5 or 6 French guide catheter is placed selectively into the cervical segment of the internal CA or vertebral artery. Sheaths, guide catheters, and microcatheters are continuously flushed using pressurized infusions. A calibrated leak balloon system and a propulsion chamber were used for intracranial catheterization until 1987. Since then, technical advances in microcatheters have allowed distal superselective catheterization. Both flow-directed and over-the-wire catheter systems have been used. Microcatheter injections allow detailed analysis of the patient's angioarchitecture. The goal has been the intranidal deposition of liquid embolic agent. More recently, for most preoperative embolizations, the goal has been arterial ligation without nidal glue deposition. Isobutyl-2-cyanoacrylate was the liquid embolic agent used until 1988; thereafter, N-butyl cyanoacrylate was used. The liquid embolic agent is mixed with Lipiodol in varying proportions according to the flow conditions. Tantalum powder is added as an opacifying agent when the concentration of Lipiodol is less than 50%. Glue injections are administered with the aid of dynamic subtraction fluoroscopy to allow easier visualization of the glue cast. At the end of the procedure, anticoagulation is reversed with injections of protamine. Dexamethasone is given (8 mg orally or intravenously three times per day) for 2 days beginning at the time of the procedure. The patients are observed in a neurointensive care unit overnight and are allowed to leave the hospital on postembolization Day 2. Induced hypotension is not used postembolization. Neurosurgical consultation is available 24 hours a day. Complications related to embolization are defined as those occurring within 1 month of the procedure. The severity of any complications was assessed using the mRS. 17 Complications are classified chronologically as those occurring within 6 hours, between 6 and 24 hours, and between 24 hours and 30 days after the procedure.
Statistical Analysis
Means and percentages are used to summarize data as appropriate. Potential associations between the occurrence of a complication and the characteristics of the patient, treatment, and AVMs were assessed using the GEE approach. 7, 19 The GEE allows regression with binary outcomes (that is, the occurrence of a complication) that are clustered within individuals by accounting for the within-person correlation of these clustered measurements. We analyzed the association of complications with each of the factors separately. Output from our GEE models is shown as an odds ratio for the occurrence of a complication along with a 95% confidence interval and a probability value. A probability value less than 0.05 was considered statistically significant.
Results
Three hundred six patients underwent 513 embolization sessions between November 1984 and September 2002 (mean 1.7 sessions per patient). Two patients with hereditary hemorrhagic telangiectasias underwent embolization for two AVMs each. The series comprised 164 male and 142 female patients ranging in age from 2 months to 77 years (mean age 34 years). One hundred fifteen patients presented with hemorrhage, 119 with seizure, and 24 with a neurological deficit; 48 patients had miscellaneous presentations such as headache or bruit. Of the 513 embolization sessions, 98 procedures were attempts only, in which a microcatheter was used but embolization was not performed. Embolization was performed in 415 procedures. A liquid embolic agent was used for 407 procedures, a liquid embolic agent and coils for two procedures, coils alone for two procedures, a liquid embolic agent and particles for two procedures, and particles alone for two procedures. Particles were exclusively used to treat the external CA supply to brain AVMs. The goal of the embolization was cure in 64 sessions, adjunctive treatment before radiosurgery in 287 sessions, adjunctive treatment before surgery in 121 sessions, and palliation of symptoms in 41 sessions.
Embolization-Induced Cure
Twenty-nine AVMs in 28 patients were cured by embolization alone. In these 29 AVMs, the intent of embolization was cure for 17 AVMs, adjunctive treatment prior to radiosurgery in 11 AVMs, and adjunctive treatment before surgery in one AVM. Twenty-five of the AVMs were smaller than 3 cm and four were 3 to 6 cm. The cure rate was 31% in the subgroup of 55 AVMs in which the goal was curative embolization.
Complications of Embolization
Sixty-two complications occurred in 56 patients (Table 1). Eight patients died. Fifty-one patients had one complication, four patients had two complications, and one patient had three complications. Seven complications occurred during an embolization attempt only. Fifty-five complications were associated with, but not always causally related to, deposition of an embolic agent. Fifty-four of these were associated with liquid embolic injection, and one was associated with coil occlusion of a dysplastic, aneurysmal feeding artery supplying an AVM in a patient presenting with two hemorrhages. Forty-eight complications were neurological (that is, exhibiting neurological symptoms and signs). Of the neurological complications, 25 (including seven deaths) were permanent and 23 were transient. The rate of death and any permanent neurological morbidity due to embolization, including attempts only, was 7.5% per patient. The rate of death and any permanent disabling neurological morbidity (mRS Score 3-5) was 3.9% per patient. The eight deaths that occurred in this series were caused by hemorrhage in six patients and ischemia in two patients (Table 2) . Of the six hemorrhages, five were parenchymal and one was subarachnoid and intraventricular. Of the two ischemic injuries, one was arterial and the other venous. Among the patients who died, five patients' physical condition deteriorated within 24 hours of the procedure. In the other three patients, physical condition deteriorated at 4 days in one and at 1 month in two patients. Permanent disabling neurological deficits were due to hemorrhage in three patients and to arterial ischemia in one patient. The last death related to embolization was in 1994 and the last incident of disabling neurological morbidity occurred in 1995. The goal of embolization did not significantly affect the complication rate.
Complications occurred in all three phases of the embolization process. Endovascular Approach. Ten (16%) of 62 complications occurred during microcatheter exploration before embolization. Six microcatheter-related perforations occurred while attempting to gain position for glue injection. Five of these perforations were in feeding arteries. Two of these occurred in lenticulostriate perforating arteries, one in a middle cerebral artery cortical branch, one in a posterior cerebral artery cortical branch, and one in the posterior inferior cerebellar artery. All perforations were initially managed by immediate reversal of induced anticoagulation with the aid of protamine. When the perforation was diagnosed, the microcatheter tip was extravascular in three patients and intravascular in one patient. In the first patient in whom the tip was extravascular, the microcatheter was left in place and cut off at the groin. In the second patient, the arterial perforation was sealed with glue, the microcatheter was removed, and the artery remained patent. In the third patient in whom the tip was extravascular, the microcatheter was left in place to occlude the perforation and allow formation of subarachnoid clot around the perforation. The microcatheter was then slowly removed without any sequela. In the one patient in whom the microcatheter tip was intravascular, there was extravasation of the contrast agent, and the artery was immediately occluded with liquid embolic agent. All five patients tolerated the perforation without a neurological deficit. The sixth perforation occurred in a flow-related basilar bifurcation aneurysm while manipulating a microcatheter to a posterior cerebral artery branch supplying an AVM. Although the microcatheter did not enter the aneurysm, the patient suffered an intraprocedural SAH and intraventricular hemorrhage due to straightening of the parent artery and traction on the aneurysm dome. Both pupils became fixed and dilated while the patient lay on the angiography table. Despite insertion of an external ventricular drain, the patient suffered brain death and care was withdrawn.
Three patients experienced focal neurological deficits after microcatheter exploration without embolization. Two of the deficits were transient and the other was a permanent small visual scotoma. One patient experienced shortness of breath after protamine administration but recovered promptly.
Embolization. Thirty-eight (61%) of 62 complications were diagnosed during the embolization procedure or when the patient recovered from general anesthesia. Nineteen complications were ischemic. Two deaths were due to ischemic injury. The first death in a patient with a right hemispheric AVM was attributed to technical equipment failure. To perform the glue injection procedure that led to the complication, the guide catheter had been placed in the left cervical internal carotid artery and the microcatheter approached the AVM through the anterior communicating artery. During glue injection, a proximal microcatheter hole allowed diffuse glue embolization into normal arteries in both cerebral hemispheres. The other ischemia-related death occurred in a patient with a high-flow AVF in the right frontal lobe. Despite induced hypotension, an 87% glue mixture, and bilateral CA compression, glue escaped into the superior sagittal and right transverse sinuses. Progressive venous congestion and venous hemorrhagic infarction occurred despite arterial embolization, which was performed to decrease flow through the AVF and thereby reduce the venous congestion. Ten of the remaining 17 ischemic injuries were permanent and seven were transient. One permanent ischemic injury produced a disabling neurological deficit due to an infarction in the posterior limb of the internal capsule. There were four instances of glue reflux proximal to the tip of the microcatheter: one was asymptomatic and three led to permanent visual field defects.
Of the six patients with hemorrhagic complications, four were left with a permanent neurological deficit. Two of these four patients experienced permanent disabling neurological deficits after undergoing a lifesaving craniotomy for a large parenchymal hematoma.
There were nine microcatheter-related complications associated with the glue injection. Eight microcatheters were embedded in the glue cast. One calibrated leak balloon catheter could not be removed because of catheter-induced vasospasm. Microcatheter fragments were removed in two patients. In the first patient a distal microcatheter fragment was removed with a snare. The other patient required removal of microcatheter fragments thought to be responsible for cardiac arrythmia. No permanent neurological complications occurred due to retained microcatheters; however, two patients experienced temporary worsening of neurological function. One patient suffered temporary hearing loss when the microcatheter was glued in the anterior inferior cerebellar artery. The other patient, who had presented with a progressive neurological deficit, initially experienced worsening of a preexisting hemiparesis, but at the 1-year follow-up examination exhibited much better function than that measured at baseline. In general, patients with retained microcatheters were treated with aspirin for 3 months.
Three complications were nonneurological. In one patient embolization was stopped due to equipment failure. Two patients had pulmonary glue emboli, and one of these experienced delayed transient respiratory failure.
Postembolization. Fourteen (23%) of 62 complications occurred during the postembolization period; these complications were defined as delayed deterioration after an initial uneventful recovery from the embolization procedure. Five patients died of large parenchymal hematomas: one at 5 hours, one at 6 hours, one at 4 days, and two at 1 month postembolization. Three of these five patients died despite undergoing a craniotomy for hematoma evacuation. In the fourth an external ventricular drain was inserted, but the patient died of a thalamic/midbrain hematoma. The fifth patient received palliative treatment for a large temporoparietal hematoma causing transtentorial herniation. Two other parenchymal hemorrhages led to a permanent disabling neurological deficit in one patient and a complete recovery after craniotomy in the second patient. A retrospective review of angiograms obtained during the embolization procedure did not show any residual angioarchitectural weak point such as an intranidal aneurysm, which could predispose to postembolization hemorrhage by rerouting blood flow. Five of the seven patients had evidence of venous glue deposition.
Five patients suffered ischemic injuries. None of these was permanently disabling. One patient had an arterial infarction due to delayed closure of the P 2 segment of the posterior cerebral artery. In two of the four remaining patients there was angiographic or computerized tomography evidence of thrombosis in the veins draining the AVM. One of the remaining two patients received anticoagulant medication because there was clinical suspicion of venous thrombosis. One patient, in whom severe headache developed due to a thrombosed AVM draining vein, required hospitalization and treatment with dexamethasone. One patient suffered a seizure associated with transient aphasia.
Types of embolization complications can be grouped by the stage of the embolization process. During the endovascular approach, microcatheter perforations predominated. During embolization, glue injection led to predominately arterial ischemia and microcatheter gluing. During the postembolization period, delayed hemorrhages due to venous glue deposition and symptomatic venous thrombosis predominated.
Factors Associated With Complications
Statistical analysis showed that only three factors were significantly associated with embolization-related complications: a nidus located in an eloquent location of the brain, a pure fistula or a nidus with a fistulous component, and venous penetration of the glue cast (Table 3) .
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Discussion
The rates of mortality and morbidity associated with embolization of a brain AVM in large clinical series are listed in Table 4 . 1, 5, 6, 8, 9, 15, 16 Frizzel and Fisher 5 summarized the morbidity and mortality rates for 1246 embolized brain AVMs that had been described in 32 reports published between 1969 and 1993. The mortality rate was 1% and the morbidity rate was 8%. No difference was found in these rates prior to and after 1990; however, because this review summarized reports spanning 35 years, there was tremendous variation in the AVM classification, embolization technique, and embolization materials used. More recent reports have shown mortality rates ranging from 1.1 to 3.7% and morbidity rates ranging from 3.8 to 14%.
The types of embolization-related complications mentioned in the paper by Frizzel and Fisher 5 included arterial perforation and dissection, normal artery embolization, and venous and dural sinus embolization. The causes of these complications were not documented, however. The existing literature concentrates on factors leading to embolizationrelated hemorrhage, specifically passage of glue into nidus draining veins and resulting hemodynamic changes. Picard, et al., 11 reported 15 cases of spontaneous hemorrhage in 492 embolized brain AVMs. Three features of the embolization procedure were associated with hemorrhage: volume of injected glue greater than 1 ml, venous embolization, and postembolization venous stagnation in and/or around the nidus. In three cases, the hemorrhage occurred during the embolization procedure. The authors speculated that acute intraprocedural hemorrhage could be due to vessel wall injury during microcatheter retrieval after glue injection. In the remaining 12 cases, hemorrhage occurred between 1 and 72 hours postembolization. Deruty and colleagues 2 reported a series of 67 patients treated with surgery, radiosurgery, embolization, or combinations of these procedures. In four of the five cases of postembolization hemorrhage, postembolization angiography demonstrated occlusion of the main nidal draining vein. In three of the five patients, the hemorrhage occurred during the embolization procedure. In the remaining two patients, the hemorrhage occurred at 2 and 5 days postembolization. Debrun and associates 1 also cautioned against abrupt occlusion of the nidal draining vein. In their series, one of the two embolization-related deaths was due to partial venous outlet occlusion.
The other major cause of embolization-related complications is ischemia. Ischemia can be arterial or venous. The two mechanisms of arterial ischemia are antegrade and retrograde occlusion. 16 Antegrade occlusion occurs when glue occludes an unrecognized normal artery distal to the nidus or occludes unrecognized normal arterial branches that are proximal to the nidus but distal to the microcatheter tip. Retrograde occlusion occurs when glue refluxes proximal to the microcatheter tip and occludes normal arteries. Another possible mechanism of normal artery occlusion is the release of small amounts of N-butyl cyanoacrylate during microcatheter removal, either as a droplet dislodged from the microcatheter tip or one expressed from the microcatheter as it is removed through bends of the catheterized artery. 9 Duckwiler and colleagues 3 reported four cases of venous thrombosis/occlusion with neurological sequelae occurring longer than 1 week after embolization. Two patients had AVFs and two had vein of Galen malformations. No glue passage into draining veins during the embolization procedure occurred in these patients. The authors have hypothesized that embolization produced venous thrombosis by decreasing blood flow within the venous outlet of the malformation.
Hartmann, et al., 6 reported on the risk of endovascular treatment of brain AVMs in 233 patients. They found a mortality rate of 1% and a rate of 14% for new neurological deficits. Only 2% of new neurological deficits were persistent and disabling. The authors found that increasing patient age, absence of a pretreatment neurological deficit, and number of embolization sessions were associated with new postembolization neurological deficits. Our study did not corroborate their findings.
Taylor and colleagues 15 reported complications of preoperative embolization of brain AVMs. Two hundred one patients underwent 339 embolization procedures in which a variety of embolic agents were used, including polyvinyl alcohol particles, N-butyl cyanoacrylate, detachable coils, and the liquid polymer Onyx (Micro Therapeutics, Inc., Irvine, CA). Death occurred in 2% of patients and permanent neurological deficit in 9% of patients. None of the demographic, anatomical, or procedural factors that the authors studied was associated with a poor outcome.
In the analysis of our series, we found that location of the nidus in an eloquent part of the brain, a pure fistula or a fistulous nidal component, and glue deposition in nidal draining veins were associated with complications. Embolization of AVMs in eloquent locations of the brain can lead to ischemic injury in tissue adjacent to the nidus. Before the introduction of newer, variable-stiffness microcatheters, in our experience, many glue injections were performed from a prenidal position by using a free-flow technique. Small normal arteries supplying eloquent cortex may not have been visualized, especially when using the poorer angiographic images obtained in procedures performed with neurolept anesthesia. Using general anesthesia and, when possible, a wedged intranidal microcatheter position, the last ischemic injury that produced death or disabling morbidity occurred in 1994. Since then, 145 embolization procedures have been performed in AVMs located in eloquent regions without resulting in death or disabling morbidity. We believe that embolization can be safely performed in AVMs located in eloquent locations of the brain.
A pure AVF is a direct communication between an artery and a vein without an interposed plexiform nidus. When there is a single pathological communication, the lesion is ideally suited for endovascular therapy with a high cure rate. 18 Nevertheless, fistulas can be high-flow shunts with enlarged feeding arteries that are not suitable for wedged microcatheter positions that produce flow control. Therefore, accurate glue placement in the shunting zone of a highflow AVF can be challenging. Embolization of these lesions often requires higher glue concentrations as well as higher injection pressures. The glue injection time is also shorter and, therefore, decision making must often be very rapid. For these reasons, either overshooting the shunting zone into the draining vein or refluxing into normal arteries is possible. Additionally, these high-flow shunts often require the use of stiffer and larger-diameter over-the-wire microcatheter systems with their attendant risks of arterial injury. An adequate distance between the microcatheter tip and the arteriovenous shunting zone is crucial for safe embolization of high-flow AVFs. Some AVMs have mixed fistulous and plexiform components. An unrecognized fistulous component can lead to embolization of the nidal vein. Microcatheter injections administered while the patient is in a state of general anesthesia have improved our ability to detect fistulous components of a mixed fistulous-plexiform nidus.
Glue deposition in nidal draining veins is a risk factor for embolization-related complications in our experience and also in the literature. In the 12 complications in this series that led to death or a disabling neurological deficit, eight involved glue passage into draining veins. We found microcatheter injections in conjunction with high magnification and general anesthesia extremely useful to clarify the transition from the nidus to the draining vein. This analysis allows us to predict where venous glue entry is likely to occur and to stop or pause the glue injection as necessary. The last postembolization hemorrhage producing death or disabling morbidity occurred in 1995.
Our philosophy of AVM embolization has evolved during the years of this study. For AVMs with a nidus smaller than 3 cm, we favor single modality treatment, whether it be surgery, radiosurgery, or embolization. We select embolization if cure is a reasonable expectation from this treatment. Nidi smaller than 3 cm that have a single dominant feeding artery have a high chance of cure with embolization. 18 Additionally, if the diagnostic angiogram demonstrates intranidal aneurysms or pseudoaneurysms, embolization can be directed toward these angioarchitectural weak points before more definitive therapy.
For AVMs in which the nidus is larger than 3 cm, in our experience, curative embolization has been rare. Instead, embolization has an adjunctive role in a multimodality treatment program. Prior to radiosurgery, embolization produces a targeted size reduction. Prior to surgery, embolization decreases blood flow through the nidus, thereby making perinidal dissection less bloody and tedious. Less frequently, embolization can occlude deep arteries that feed an AVM nidus, such as lenticulostriate perforating arteries, which would be encountered toward the end of nidus dissection. More recently, the goal of preoperative embolization has been pure arterial ligation without nidal glue deposition to minimize the risk of venous glue placement. 18 Additionally, pure arterial ligation allows the nidus to remain compressible during AVM resection. There were no statistically significant differences in overall complication rates when embolization was used with the intent to cure or palliate symptoms or as an adjunct to surgery or radiosurgery. Nevertheless, 10 of the 12 complications leading to death or disabling morbidity occurred in patients who underwent embolization before radiosurgery. We speculate that the goal of nidal size reduction by nidal glue placement increased the risk of venous glue deposition.
The statistical analysis did not demonstrate improvements in the overall complication rate when comparing the first half of the series with the second half. In the latter half, however, there was an important, clinically relevant reduction in embolization complications producing death or permanent disabling morbidity. We believe this is not only a reflection of improved angiographic equipment and microcatheters but, more importantly, is proof of the value of clinical judgment and experience. Arteriovenous malformations in the brain should be managed by a multidisciplinary group that has a special interest in and commitment to patients with neurovascular diseases.
Conclusions
The significant factors that lead to complications associated with the embolization of AVMs of the brain are location in an eloquent part of the brain, presence of a fistula, and venous glue deposition. The overall rate of embolization-related mortality and disabling morbidity is 3.9% per patient.
